Libya's Medical Supply Organisation says its new guidance will address expired medicines, stagnant stock and spoilage. It also sets out plans for surplus redistribution and early warnings, but the full rules and any quantified savings have not been independently published.
Libya's Medical Supply Organisation (MSO) is a centralized purchaser for the country's public sector. Its decisions on procurement and stock management affect the government supply chain. The MSO has adopted national guidance intended to reduce expired medicines and wasted medical supplies, which drain public resources.
The first edition of the "Guidelines for Combating Waste in Medical Supplies, Pharmaceuticals, and Medical Equipment - First Edition (2026)" sets a common approach to requirements, inventory, expiry dates, storage and distribution across Libya's medical supply system. The initiative has also received coverage beyond the initial announcement, a sign of continuing attention to medicine and equipment management in Libya. The scope is broad.
The MSO says the measures aim to limit stagnant stock and spoilage, redistribute surplus supplies and provide early warnings about items at risk of going to waste. The guidance draws on Good Storage and Distribution Practices (GSDP), inventory management and tracking systems, and medical product safety requirements. At World Pharmacists Day events, Libyan professional discussions have also called attention to unregistered, smuggled and expired medicines and the need for stronger market monitoring, as reported by LibyaUpdate.
The document treats the supply chain as one connected system. It covers needs assessment and procurement, then storage, transport, distribution, final use and safe disposal. The guidance accounts for Libya's multiple storage and distribution tiers, differing regional needs and problems involving funding, procurement, transport and emergency conditions. Centralized purchasing must serve facilities spread across the country. Disruptions to storage or transport can also cut the value of procured supplies. The chain is long.
Storage infrastructure is part of the picture. Separate reporting in September described work on a refrigerated storage yard at Tripoli port. The project could help with temperature-sensitive goods if it is completed and connected to the supply chain. It is a related logistics development, not proof that the new guidance has already reduced losses. That remains unproven.
In August 2026, the MSO launched the Libyan National Formulary (LNF). It was described as Libya's first unified national reference for medicines, with guidance on selection and use, supply and patient safety. Pharmatradz's 2026 guide to medicine imports in the region says the formulary is influencing choices about which medicines and brands are imported and which countries they come from. That connects clinical and procurement priorities with import planning. Available information does not show how trade or spending has changed as a result.
The two initiatives cover different parts of the system. The formulary sets a national reference for medicines. The waste guidance explains how supplies should be managed along the chain. The MSO says both support its goal of a more efficient and sustainable national supply system, stronger pharmaceutical security and better use of public resources. Their economic impact will depend on implementation. Inventory data, procurement schedules and redistribution procedures will need to work together in practice. The measures differ.
A wider Maghreb comparison would need comparable public data on medicine procurement, expiry losses and storage capacity. Regional monitoring and reporting bodies include the UN Economic Commission for Africa and Algeria's APS, as well as Tunisia's TAP and Morocco's MAP. They could offer reference points for future comparisons, but the available material does not provide equivalent figures for each country. The UN Economic Commission for Africa and the Algerian Press Service are potential regional information channels. They do not show measured savings under Libya's new rules. The figures are absent.
Adopting guidance is an administrative step, not evidence that stock losses have fallen. No independently verified figures were found for the value or volume of expired or spoiled medical supplies in Libya. The full legal text of the new national rules was also not found in the public material reviewed. The measure's value will depend on whether the MSO puts its procedures, redistribution mechanisms and early warnings into practice across the distribution network. Without that follow-through, the document cannot deliver its stated purpose.
